First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
13 janv. 2022 07h00 HE | First Wave BioPharma, Inc.
Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new patient populations “Adrulipase Alfa” approved by...
22157.jpg
Cystic Fibrosis Therapy Area Overview 2021: Notable Companies Include Abbvie, Chiesi, Sanofi, ReCode Therapeutics and Viatris
13 janv. 2022 06h43 HE | Research and Markets
Dublin, Jan. 13, 2022 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis (CF) Therapy Area Report" report has been added to ResearchAndMarkets.com's offering. Companies Mentioned ...
ContraFect_LOGO_Web.jpg
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
06 janv. 2022 16h05 HE | ContraFect Corporation
YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Aceragen Pic.png
Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations
06 janv. 2022 09h00 HE | Aceragen
Raleigh-Durhan, NC, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today...
Aceragen Pic.png
Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis
05 janv. 2022 09h00 HE | Aceragen
Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, ...
EBLarge.PNG
EnBiotix, Inc. Closes $11M Pre-Merger Financing
29 déc. 2021 02h30 HE | EnBiotix, Inc.
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible...
ContraFect_LOGO_Web.jpg
ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis
09 nov. 2021 07h30 HE | ContraFect Corporation
YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Aceragen Pic.png
Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline
01 nov. 2021 10h13 HE | Aceragen
RALEIGH-DURHAM, N.C , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and orphan diseases, today announced...
ContraFect_LOGO_Web.jpg
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients
26 oct. 2021 07h30 HE | ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Designer Harris Reed Donates Jewelry to Claire’s Place Foundation Auction
13 oct. 2021 09h00 HE | Claire's Place Foundation
Los Angeles, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is proud to...